These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 33986964)
1. Ceftriaxone as an Alternative Therapy for the Treatment of Methicillin-Susceptible Barber KE; Cramer RA; Bell AM; Wagner JL; Stover KR Case Rep Infect Dis; 2021; 2021():8884685. PubMed ID: 33986964 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. Patel UC; McKissic EL; Kasper D; Lentino JR; Pachucki CT; Lee T; Lopansri BK Int J Clin Pharm; 2014 Dec; 36(6):1282-9. PubMed ID: 25186790 [TBL] [Abstract][Full Text] [Related]
3. Ceftriaxone for the Treatment of Methicillin-susceptible Lowe RA; Barber KE; Wagner JL; Bell-Harlan AM; Stover KR J Pharmacol Pharmacother; 2017; 8(3):140-144. PubMed ID: 29081626 [TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infections Due to Methicillin-Susceptible Alsowaida YS; Benitez G; Bin Saleh K; Almangour TA; Shehadeh F; Mylonakis E Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326838 [TBL] [Abstract][Full Text] [Related]
6. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Hamad Y; Connor L; Bailey TC; George IA Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944 [TBL] [Abstract][Full Text] [Related]
7. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus. So W; Crandon JL; Nicolau DP Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307 [TBL] [Abstract][Full Text] [Related]
8. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible Carr DR; Stiefel U; Bonomo RA; Burant CJ; Sims SV Open Forum Infect Dis; 2018 May; 5(5):ofy089. PubMed ID: 30568987 [TBL] [Abstract][Full Text] [Related]
9. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Hamad Y; Nickel KB; Olsen MA; George IA Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150 [TBL] [Abstract][Full Text] [Related]
10. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus. Wieland BW; Marcantoni JR; Bommarito KM; Warren DK; Marschall J Clin Infect Dis; 2012 Mar; 54(5):585-90. PubMed ID: 22144536 [TBL] [Abstract][Full Text] [Related]
11. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Ben-David D; Novikov I; Mermel LA Infect Control Hosp Epidemiol; 2009 May; 30(5):453-60. PubMed ID: 19344266 [TBL] [Abstract][Full Text] [Related]
12. A Retrospective Analysis of Treatment and Clinical Outcomes among Patients with Methicillin-Susceptible Staphylococcus aureus Bloodstream Isolates Possessing Detectable Jones D; Elshaboury RH; Munson E; Dilworth TJ Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038267 [No Abstract] [Full Text] [Related]
13. Clinical Outcomes of Daptomycin Versus Anti-Staphylococcal Beta-Lactams in Definitive Treatment of Methicillin-susceptible Staphylococcus aureus Bloodstream Infections. Agnello S; Wardlow LC; Reed E; Smith JM; Coe K; Day SR Int J Antimicrob Agents; 2021 Aug; 58(2):106363. PubMed ID: 34033912 [TBL] [Abstract][Full Text] [Related]
14. Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus. Gern BH; Greninger AL; Weissman SJ; Stapp JR; Tao Y; Qin X Ann Clin Microbiol Antimicrob; 2018 Feb; 17(1):5. PubMed ID: 29463249 [TBL] [Abstract][Full Text] [Related]
15. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone. Winans SA; Luce AM; Hasbun R Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435 [TBL] [Abstract][Full Text] [Related]
16. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of ceftriaxone for the treatment of methicillin-susceptible Staphylococcus aureus: is it a viable treatment option? Heffernan AJ; Sime FB; Lim SMS; Adiraju S; Wallis SC; Lipman J; Grant GD; Roberts JA Int J Antimicrob Agents; 2022 Mar; 59(3):106537. PubMed ID: 35093539 [TBL] [Abstract][Full Text] [Related]
18. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Martínez-Aguilar G; Hammerman WA; Mason EO; Kaplan SL Pediatr Infect Dis J; 2003 Jul; 22(7):593-8. PubMed ID: 12867833 [TBL] [Abstract][Full Text] [Related]
19. Early Administration of Adjuvant β-Lactam Therapy in Combination with Vancomycin among Patients with Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: A Retrospective, Multicenter Analysis. Casapao AM; Jacobs DM; Bowers DR; Beyda ND; Dilworth TJ; Pharmacotherapy; 2017 Nov; 37(11):1347-1356. PubMed ID: 28949410 [TBL] [Abstract][Full Text] [Related]
20. Ceftriaxone versus antistaphylococcal antibiotics for definitive treatment of methicillin-susceptible Staphylococcus aureus infections: a systematic review and meta-analysis. Yetmar ZA; Razi S; Nayfeh T; Gerberi DJ; Mahmood M; Abu Saleh OM Int J Antimicrob Agents; 2022 Jan; 59(1):106486. PubMed ID: 34839007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]